Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New allergy drug shows promise in early trial

NCT ID NCT03570957

Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a single dose of the investigational drug MT-2990 in 75 adults with seasonal allergic rhinitis triggered by Japanese cedar pollen. The main goals were to check the drug's safety, how the body processes it, and whether it can reduce allergy symptoms when patients are exposed to pollen in a controlled chamber. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MT-2990
What this could lead to
If successful, this could lead to a new treatment option for seasonal allergic rhinitis caused by Japanese cedar pollen.
What could go wrong
This is an early Phase 1 study with only 75 participants, so results may not confirm effectiveness or safety in larger populations. The drug may cause side effects or fail to provide meaningful symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

75 people

The number who actually took part.

Started

Jul 2018

Finished

Dec 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A body weight of 40 to 100 kg for female or 45 to 100 kg for male * A body mass index of 18 to 30 kg/m2 * Subjects who have current history of JC-SAR in previous 2 consecutive years. * Presence (CAP-RAST: ≥2) of IgE specific to Japanese cedar pollens and absence (CAP-RAST: ≤1) of IgE specific to other 4 allergens * Presence of at least 2 symptoms, which are moderate to very severe, in 4 nasal symptoms (runny nose, sneezing, blocked nose, itchy nose) at any time point during allergen exposure in EEC at screening period Exclusion Criteria: * Presence of any symptoms of allergic rhinitis within 1 year except scattering season of cedar pollen or cypress pollen * Subjects who have persistent symptom caused by allergen exposure in EEC at screening period until Day 1 (pre-dose) * Underwent nasal surgery (include laser surgery) to improve nasal symptoms within 2 years * Underwent specific immunotherapy or non-specific immunotherapy within 5 years * Underwent medication of anti-histamine, oral mast cell stabilizer, leukotriene receptor antagonist, prostaglandin D2/thromboxane A2 receptor antagonist, Th2 cytokine inhibitor, corticosteroid (oral form, intra-nasal form, ocular form), or vasoconstrictor within 4 weeks * Underwent medication of corticosteroid (injection form) or anti-IgE antibody within 6 months * Subject who is concerned about exacerbation of the physical condition due to allergen exposure in EEC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Seasonal allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Seasonal allergic rhinitis

Contacts and locations

Locations

  • Investigational Site

    Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.